EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 256 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR New on NCI Websites for July 2019 July 2, 2019 Visits to Online Breast Cancer Communities Could Help Policy Makers and... February 11, 2021 What the Budget 2021 means for research October 29, 2021 How My Advanced Colorectal Cancer Diagnosis Led Me to Patient Advocacy March 3, 2021 Load more HOT NEWS ESMO Highlights Key Issues for Patients with Cancer and Their Carers... GreaterGood Has Donated More Than 2 Million Masks to Frontline Workers... Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... Quantitative Summary of QoL Data Confirms Immune Checkpoint Inhibitor Therapy Is...
